Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28507911 | 0.86 | SSTR4 (0.40) | MAP4K4PARP1IRAK4PIK3CDPIK3CA | |
| SCHEMBL30618082 | 0.86 | MAP4K4 (0.38) | MAP4K4PARP1IRAK4PIK3CDPIK3CA | |
| SCHEMBL30826990 | 0.81 | PARP1 (0.37) | MAP4K4NR1H2PARP1IRAK4PIK3CD | |
| SCHEMBL2923586 | 0.78 | TLR9 (0.50) | IRAK4KITEPHA2KDREPHB4 | |
| SCHEMBL2920961 | 0.78 | TLR9 (0.50) | IRAK4KITEPHA2KDREPHB4 | |
| SCHEMBL29611977 | 0.77 | TSHR (0.36) | MAP4K4PARP1MEN1KMT2A | |
| SCHEMBL8140446 | 0.77 | PARP1 (0.43) | NR1H2PARP1 | |
| SCHEMBL7374803 | 0.77 | PARP1 (0.40) | MAP4K4NR1H2PARP1MEN1KMT2A | |
| SCHEMBL30826881 | 0.76 | PARP1 (0.35) | NR1H2PARP1MEN1KMT2A | |
| SCHEMBL30945064 | 0.76 | JAK3 (0.47) | JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680114-B2 | AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
| CN-1882347-A | AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2006-12-20 | — | — | CN | disclosed |
| EP-1684694-A2 | AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | MAP4K4 141/4885NR1H2 987/4885PARP1 1630/4885 |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | MAP4K4 141/4885NR1H2 987/4885PARP1 1630/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | MAP4K4 141/4885NR1H2 987/4885PARP1 1630/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | MAP4K4 82/4885NR1H2 1737/4885PARP1 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.